ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 761

Increased Expression of the TNF Superfamily Member LIGHT/TNFSF14 and Its Receptor (TNFRSF14) in Patients with Systemic Sclerosis

Otylia Kowal-Bielecka1, Ewa Gindzienska-Sieskiewicz1, Oliver Distler2, Joanna Reszec3, Suzana Jordan2, Pawel Bielecki4, Andzrzej Sieskiewicz4, Agnieszka Sulik1 and Krzysztof Kowal5,6, 1Department of Rheumatology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland, 2Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 3Department of Medical Pathomorphology, Department of Medical Pathomorphology, Medical University of Bialystok, Bialystok, Poland, 4Department of Otolaryngology, Medical University of Bialystok, Bialystok, Poland, 5Department of Allergology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland, 6Department of Experimental Allergology and Immunology, Medical University of Bialystok, Bialystok, Poland

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: scleroderma and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The TNF Superfamily member LIGHT (TNFSF14) regulates immune response and angiogenesis. Moreover, recent studies indicate that interactions of LIGHT with its receptor, TNFRSF14, might also play a role in regulation of tissue remodeling. Since autoimmunity, vascular injury and fibrosis are key elements of the pathogenesis of systemic sclerosis (SSc) we hypothesized that LIGHT might be involved in development of SSc. This study was aimed to assess potential role of LIGHT in SSc through evaluation of: 1). expression of LIGHT and its receptor, TNFRSF14, in skin biopsies and 2) associations between serum concentration of LIGHT and clinical features in SSc patients.

Methods: Expression of LIGHT and its receptor, TNFRSF14, was investigated by means of immunohistochemistry, and evaluated semiquantitatively (score from 0 to 3), in skin biopsies from 18 SSc patients and 9 healthy controls. Serum levels of LIGHT were measured using commercially available ELISA kits in 320 patients with SSc and 50 control subjects.

Results: Expression of both, LIGHT and TNFRSF14 was significantly higher in skin biopsies from SSc patients as compared with healthy controls (p<0.05). Patients with early SSc (</= 3 years from the first non-Raynaud’s phenomenon, n=13) showed significantly higher skin expression of TNFRSF14 (p<0.05) and tended to have greater skin expression of LIGHT (p=0.06) as compared with SSc patients with longer disease (n=5).

The mean serum concentration of LIGHT was significantly higher in SSc patients as compared with the controls (p<0.05). Moreover, mean serum concentration of LIGHT was significantly higher in SSc patients with digital ulcers (DUs) as compared with SSc patients without DUs, patients without anti-centromere antibodies (ACA) as compared with those with ACA, patients with muscle involvement (defined by elevated serum CK levels) compared with patients without CK elevation and in patients receiving steroids, as compared with those without steroid therapy (p<0,05 for all comparisons). In addition, the mean concentration of LIGHT was significantly higher in male patients as compared with female SSc patients (p<0,05). There were also statistically significant (p<0.05) although very weak correlations between serum concentration of LIGHT and skin involvement (modified Rodnan skin score (mRSS); R-Spearman = 0,13;), erythrocyte sedimentation rate (ESR; R-Spearman = 0,15), and, inverse, with diffusing capacity of the lungs for CO (DLCO; R-Spearman = -0,22). We could not find any significant associations between serum LIGHT concentrations and other SSc features, including subtype of SSc, disease duration, presence of interstitial lung disease, pulmonary hypertension, or other antibodies. In multivariate regression analysis including, as predictors, DUs, ACA, serum CK elevation, steroid therapy, mRSS, DLCO, ESR, and sex, only presence of DUs and DLCO were independently associated with serum concentration of LIGHT (p<0,05 for both) .

Conclusion: These data provide the first evidence of overexpression of LIGHT and its receptor in SSc and suggest that LIGHT-TNFRSF14 axis might contribute to the pathogenesis of SSc. Increased serum concentrations of LIGHT seem to reflect vascular injury in SSc.


Disclosure: O. Kowal-Bielecka, None; E. Gindzienska-Sieskiewicz, None; O. Distler, 4 D Science, Actelion, Active Biotec, Bayer, Biogen Idec, Boehringer Ingelheim Pharma, BMS, ChemomAb, EpiPharm, Ergonex, espeRare foundation, GSK,Roche-Genentech, Inventiva, Lilly, medac, MedImmune, Mitsubishi Tanabe, Pharmacyclics, Pfizer, Sanofi, Seroda, 2; J. Reszec, None; S. Jordan, None; P. Bielecki, None; A. Sieskiewicz, None; A. Sulik, None; K. Kowal, None.

To cite this abstract in AMA style:

Kowal-Bielecka O, Gindzienska-Sieskiewicz E, Distler O, Reszec J, Jordan S, Bielecki P, Sieskiewicz A, Sulik A, Kowal K. Increased Expression of the TNF Superfamily Member LIGHT/TNFSF14 and Its Receptor (TNFRSF14) in Patients with Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/increased-expression-of-the-tnf-superfamily-member-lighttnfsf14-and-its-receptor-tnfrsf14-in-patients-with-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-expression-of-the-tnf-superfamily-member-lighttnfsf14-and-its-receptor-tnfrsf14-in-patients-with-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology